52311-50-9

Basic information

• Product Name: 2-CHLORO-4-ETHOXYPYRIDINE
• Synonyms: 2-CHLORO-4-ETHOXYPYRIDINE
• CAS NO: 52311-50-9
• Molecular Formula: C₇H₈ClNO
• Molecular Weight: 157.6
• Mol File: 52311-50-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 55-57 °C
• Boiling Point: 230.9 °C at 760 mmHg
• Flash Point: 93.5 °C
• Appearance: /
• Density: 1.166 g/cm³
• Vapor Pressure: 0.0971mmHg at 25°C
• Refractive Index: 1.512
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.25±0.10(Predicted)
• CAS DataBase Reference: 2-CHLORO-4-ETHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-4-ETHOXYPYRIDINE(52311-50-9)
• EPA Substance Registry System: 2-CHLORO-4-ETHOXYPYRIDINE(52311-50-9)

Safety Data

• Hazardous Substances Data: 52311-50-9(Hazardous Substances Data)

Usage

Uses

2-Chloro-4-ethoxypyridine is a useful research chemical.

InChI:InChI=1/C7H8ClNO/c1-2-10-6-3-4-9-7(8)5-6/h3-5H,2H2,1H3

Upstream product

• 26452-80-2 2,4-dichloropyridine 
• 141-52-6 sodium ethanolate 
• 153034-86-7 2-chloro-4-iodopyridine 
• 17368-12-6 2-chloropyridin-4-ol 
• 75-03-6 ethyl iodide 
• 23056-36-2 2-chloro-4-nitropyridine 
• 73583-37-6 2-chloro-4-bromopyridine 
• 64-17-5 ethanol 

Downstream Products

• 1419223-36-1 N-(4-ethoxypyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1627856-64-7 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1- trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide 
• 52311-48-5 5-bromo-2-chloro-4-ethoxypyridine 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS

Abdominal pain and abnormal bowel habits represent major symptoms for irritable bowel syndrome (IBS) patients that are not adequately managed. Although the etiology of IBS is not completely understood, many of the functions of the gastrointestinal (GI) tract are regulated by the enteric nervous system (ENS). Inflammation or stress-induced expression of growth factors or cytokines may lead to hyperinnervation of visceral afferent neurons in GI tract and contribute to the pathophysiology of IBS. Rearranged during transfection (RET) is a neuronal growth factor receptor tyrosine kinase critical for the development of the ENS as exemplified by Hirschsprung patients who carry RET loss-of-function mutations and lack normal colonic innervation leading to colonic obstruction. Similarly, RET signaling in the adult ENS maintains neuronal function by contributing to synaptic formation, signal transmission, and neuronal plasticity. Inhibition of RET in the ENS represents a novel therapeutic strategy for the normalization of neuronal function and the symptoms of IBS patients. Herein, we describe our screening effort and subsequent structure-activity relationships (SARs) in optimizing potency, selectivity, and mutagenicity of the series, which led to the discovery of a first-in-class, gut-restricted RET kinase inhibitor, 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide (15, GSK3179106), as a clinical candidate for the treatment of IBS. GSK3179106 is a potent, selective, and gut-restricted pyridone hinge binder small molecule RET kinase inhibitor with a RET IC50 of 0.3 nM and is efficacious in vivo.

CRYSTALLINE FORMS OF 2-(4-(4-ETHOXY-6-OXO-1,6-DIHYDROPYRIDIN-3-YL)-2-FLUOROPHENYL)-N-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)ACETAMIDE

Disclosed are novel crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin- 3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.